SHORT REPORT: TREATMENT FAILURE IN HANSEN’S DISEASE

CLINTON K. MURRAY Brooke Army Medical Center, Fort Sam Houston, Texas; National Hansen’s Disease Programs, Baton Rouge, Louisiana; Medicine Specialty Services, University of Texas at Tyler, San Antonio, Texas

Search for other papers by CLINTON K. MURRAY in
Current site
Google Scholar
PubMed Close
,
M. PATRICIA JOYCE Brooke Army Medical Center, Fort Sam Houston, Texas; National Hansen’s Disease Programs, Baton Rouge, Louisiana; Medicine Specialty Services, University of Texas at Tyler, San Antonio, Texas

Search for other papers by M. PATRICIA JOYCE in
Current site
Google Scholar
PubMed Close
, and
ROBERT N. LONGFIELD Brooke Army Medical Center, Fort Sam Houston, Texas; National Hansen’s Disease Programs, Baton Rouge, Louisiana; Medicine Specialty Services, University of Texas at Tyler, San Antonio, Texas

Search for other papers by ROBERT N. LONGFIELD in
Current site
Google Scholar
PubMed Close
DOI:
https://doi.org/10.4269/ajtmh.2003.68.233
Volume/Issue:
Volume 68: Issue 2
Page(s):
233–234
Restricted access
Get Permissions

Areas of low endemicity of Hansen’s disease, such as Texas, California, and Hawaii, exist due to immigration and rare autochthonous infections. Managing this disease in these areas of low endemicity is difficult, especially in observing for relapse. The accurate diagnosis of relapse is imperative so that appropriate therapy can be promptly reinstituted and unnecessary treatment can be avoided. To assess treatment failures in an area of low endemicity, we retrospectively evaluated 113 patients with Hansen’s disease treated in southern Texas. Of 57 patients who completed therapy, 11 were later restarted on medications for this disease for presumed relapse. However, nine of the 11 were found not to have true relapses of Hansen’s disease. The accurate diagnosis of relapse of this disease is essential not only in the individual patient but also for prospective treatment trials to establish best practices.

Author Notes

Reprint requests: Clinton K. Murray, Department of Medicine, Infectious Diseases Service, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234-6200, Telephone: 210-916-5554, Fax: 210-916-0388, E-mail: Clinton.Murray@AMEDD.ARMY.MIL.
Copyright:
Copyright 2003 The American Society of Tropical Medicine 2003
Received:
01 Apr 2002
|
Accepted:
15 Aug 2002
|
Published Online:
Feb 2003
Cover The American Journal of Tropical Medicine and Hygiene
The American Journal of Tropical Medicine and Hygiene
Print ISSN:
0002-9637
  • 1

    Ooi WW, Moschella SL, 2001. Update on leprosy in immigrants in the United States: status in the year 2000. Clin Infect Dis 32 :930–937.

    • Search Google Scholar
    • Export Citation
  • 2

    U.S. Department of Health and Human Services, CDC, 2001. Summary of notifiable diseases, United States, 1999. MMWR Morb Mortal Wkly Rep 48 :1–101.

    • Search Google Scholar
    • Export Citation
  • 3

    World Health Organization, 1998. World Health Organization Expert Committee on Leprosy. Seventh Report. World Health Organ Tech Rep Ser 874.

  • 4

    Sehgal VN, Jain S, Charya SN, 1996. Persisters, relapse (reactivation), drug resistance and multidrug therapy (MDT): uniform diagnostic guidelines for leprosy are needed. J Dermatol 23 :905–907.

    • Search Google Scholar
    • Export Citation
  • 5

    Girdhar BK, Girdhar A, Kumar A, 2000. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr Rev 71 :144–153.

Past two years Past Year Past 30 Days
Abstract Views 19 19 5
Full Text Views 239 83 0
PDF Downloads 71 22 0
 
Membership Banner
 
 
 
Affiliate Membership Banner
 
 
Research for Health Information Banner
 
 
CLOCKSS
 
 
 
Society Publishers Coalition Banner
Save